Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 359

1.

Construction of a frailty index as a novel health measure in systemic lupus erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

J Rheumatol. 2019 Apr 15. pii: jrheum.181338. doi: 10.3899/jrheum.181338. [Epub ahead of print]

PMID:
30988130
2.

Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

Arthritis Rheumatol. 2019 Feb 16. doi: 10.1002/art.40859. [Epub ahead of print]

PMID:
30771242
3.

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón G, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet E.

Rheumatology (Oxford). 2019 Feb 8. doi: 10.1093/rheumatology/kez014. [Epub ahead of print]

PMID:
30753683
4.

Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story.

Urowitz MB, Su J, Gladman DD.

J Rheumatol. 2019 Feb 1. pii: jrheum.180986. doi: 10.3899/jrheum.180986. [Epub ahead of print]

PMID:
30709950
5.

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg DA, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Rheumatol. 2019 May;46(5):492-500. doi: 10.3899/jrheum.180713. Epub 2019 Jan 15.

6.

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.

Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S.

Ann Rheum Dis. 2019 Mar;78(3):372-379. doi: 10.1136/annrheumdis-2018-214043. Epub 2019 Jan 4.

7.

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.

Mendel A, Bernatsky SB, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon JP, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin PR, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet É.

Ann Rheum Dis. 2018 Dec 20. pii: annrheumdis-2018-214434. doi: 10.1136/annrheumdis-2018-214434. [Epub ahead of print] No abstract available.

8.

Disease course patterns in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Lupus. 2019 Jan;28(1):114-122. doi: 10.1177/0961203318817132. Epub 2018 Dec 8.

PMID:
30526328
9.

Correction to: Psoriasis in systemic lupus erythematosus: a single-center experience.

Tselios K, Yap KS, Pakchotanon R, Polachek A, Su J, Urowitz MB, Gladman DD.

Clin Rheumatol. 2019 Jan;38(1):269. doi: 10.1007/s10067-018-4363-0.

PMID:
30430267
10.

How can we define low disease activity in systemic lupus erythematosus?

Tselios K, Gladman DD, Urowitz MB.

Semin Arthritis Rheum. 2018 Oct 16. pii: S0049-0172(18)30485-2. doi: 10.1016/j.semarthrit.2018.10.013. [Epub ahead of print]

PMID:
30415943
11.

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Rheumatol. 2019 Feb;71(2):281-289. doi: 10.1002/art.40764. Epub 2019 Jan 18.

12.

Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?

Tselios K, Deeb M, Gladman DD, Harvey P, Akhtari S, Mak S, Butany J, Urowitz MB.

J Rheumatol. 2019 Apr;46(4):391-396. doi: 10.3899/jrheum.180124. Epub 2018 Oct 15.

PMID:
30323009
13.

Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?

Tselios K, Gladman DD, Harvey P, Akhtari S, Su J, Urowitz MB.

J Rheumatol. 2019 Jan;46(1):64-69. doi: 10.3899/jrheum.171436. Epub 2018 Aug 1.

PMID:
30068764
14.

Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.

Keeling SO, Bissonauth A, Bernatsky S, Vandermeer B, Fortin PR, Gladman DD, Peschken C, Urowitz MB.

J Rheumatol. 2018 Oct;45(10):1440-1447. doi: 10.3899/jrheum.171307. Epub 2018 Aug 1.

15.

Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720. [Epub ahead of print]

PMID:
30055090
16.

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ.

Arthritis Care Res (Hoboken). 2018 Jul 25. doi: 10.1002/acr.23712. [Epub ahead of print]

PMID:
30044551
17.

Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.

Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, Costenbader KH, Ramsey-Goldman R, Lim SS, Esdaile JM, Clarke AE, Urowitz MB, Askanase A, Aranow C, Petri M, Choi H.

Arthritis Res Ther. 2018 Jul 5;20(1):133. doi: 10.1186/s13075-018-1634-8.

18.

Monophasic Disease Course in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

J Rheumatol. 2018 Aug;45(8):1131-1135. doi: 10.3899/jrheum.171319. Epub 2018 Jun 1.

PMID:
29858240
19.

A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.

Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB.

Rheumatology (Oxford). 2018 Aug 1;57(8):1370-1376. doi: 10.1093/rheumatology/key103.

PMID:
29688532
20.

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Tselios K, Gladman DD, Harvey P, Su J, Urowitz MB.

Lupus. 2018 Aug;27(9):1415-1423. doi: 10.1177/0961203318770526. Epub 2018 Apr 17.

PMID:
29665757
21.

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Jul;27(8):1296-1302. doi: 10.1177/0961203318770018. Epub 2018 Apr 11.

PMID:
29642752
22.

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN.

Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444.

23.

Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre YS, Clarke AE.

J Rheumatol. 2018 Mar;45(3):393-396. doi: 10.3899/jrheum.170652. Epub 2018 Jan 15.

24.

Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin P, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Chatham W, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1478-1487. doi: 10.1002/acr.23509. Epub 2018 Sep 1.

PMID:
29316357
25.

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study.

Ferreira I, Croca S, Raimondo MG, Matharu M, Miller S, Giles I, Isenberg D, Ioannou Y, Hanly JG, Urowitz MB, Anderson N, Aranow C, Askanase A, Bae SC, Bernatsky S, Bruce IN, Buyon J, Clarke AE, Dooley MA, Fortin P, Ginzler E, Gladman D, Gordon C, Inanc M, Jacobsen S, Kalunian K, Kamen D, Khamashta M, Lim S, Manzi S, Merrill J, Nived O, Peschken C, Petri M, Ramsey-Goldman R, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinson K, Sturfelt GK, van Vollenhoven R, Wallace DJ, Zoma A, Rahman A.

Arthritis Res Ther. 2017 Dec 22;19(1):287. doi: 10.1186/s13075-017-1495-6.

26.

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach.

Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1294-1302. doi: 10.1002/acr.23480. Epub 2018 Aug 17.

27.

More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.

Pakchotanon R, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2018 Jan;45(1):90-94. doi: 10.3899/jrheum.170645. Epub 2017 Nov 15.

PMID:
29142038
28.

Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study.

Tselios K, Gladman DD, Su J, Ace O, Urowitz MB.

J Rheumatol. 2017 Dec;44(12):1841-1849. doi: 10.3899/jrheum.161121. Epub 2017 Nov 1.

PMID:
29093154
29.

Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis.

Tselios K, Lam WC, Urowitz MB, Gladman DD.

J Clin Rheumatol. 2018 Mar;24(2):93-94. doi: 10.1097/RHU.0000000000000600. No abstract available. Erratum in: J Clin Rheumatol. 2018 Jun;24(4):192.

PMID:
29059086
30.

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.

Kalunian KC, Urowitz MB, Isenberg D, Merrill JT, Petri M, Furie RA, Morgan-Cox MA, Taha R, Watts S, Silk M, Linnik MD.

Rheumatology (Oxford). 2018 Jan 1;57(1):125-133. doi: 10.1093/rheumatology/kex368.

PMID:
29045736
31.

Antimalarial-induced cardiomyopathy: a systematic review of the literature.

Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB.

Lupus. 2018 Apr;27(4):591-599. doi: 10.1177/0961203317734922. Epub 2017 Oct 9. Review.

PMID:
28992800
32.

Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis.

Pakchotanon R, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Mar;27(3):468-474. doi: 10.1177/0961203317726376. Epub 2017 Aug 31.

PMID:
28857717
33.

Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience.

Deeb M, Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Mar;27(3):365-371. doi: 10.1177/0961203317722411. Epub 2017 Jul 31.

PMID:
28758573
34.

Reply.

Urowitz MB, Gladman DD.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1934. doi: 10.1002/acr.23309. No abstract available.

35.

Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus.

Tselios K, Urowitz MB.

Curr Rheumatol Rev. 2017;13(3):206-218. doi: 10.2174/1573397113666170704102444. Review.

PMID:
28675998
36.

Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center.

Gu K, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2017 Aug;44(8):1173-1178. doi: 10.3899/jrheum.170072. Epub 2017 Jun 15.

PMID:
28620060
37.

Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment.

Chan K, Clarke AE, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz MB, Gladman D, Nived O, Romero-Diaz J, Petri M, Ginzler E, Fortin PR, Bae SC, Wallace DJ, Yelin EH, Bernatsky S.

Lupus. 2018 Jan;27(1):120-123. doi: 10.1177/0961203317713146. Epub 2017 Jun 8.

PMID:
28595511
38.

Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics.

Aljohani R, Gladman DD, Su J, Urowitz MB.

Clin Rheumatol. 2017 Aug;36(8):1773-1778. doi: 10.1007/s10067-017-3713-7. Epub 2017 Jun 6.

PMID:
28589322
39.

Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors.

Gladman DD, Dhillon N, Su J, Urowitz MB.

Lupus. 2018 Jan;27(1):76-81. doi: 10.1177/0961203317711012. Epub 2017 May 22.

PMID:
28530464
40.

Disease evolution in late-onset and early-onset systemic lupus erythematosus.

Aljohani R, Gladman DD, Su J, Urowitz MB.

Lupus. 2017 Oct;26(11):1190-1196. doi: 10.1177/0961203317696593. Epub 2017 Mar 12.

PMID:
28420066
41.

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Buyon J, Mahler M, Fritzler MJ.

Lupus. 2017 Sep;26(10):1051-1059. doi: 10.1177/0961203317692437. Epub 2017 Feb 23.

PMID:
28420054
42.

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease.

Al Rayes H, Harvey PJ, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z.

Arthritis Res Ther. 2017 Feb 10;19(1):31. doi: 10.1186/s13075-017-1240-1.

43.

Psoriasis in systemic lupus erythematosus: a single-center experience.

Tselios K, Yap KS, Pakchotanon R, Polachek A, Su J, Urowitz MB, Gladman DD.

Clin Rheumatol. 2017 Apr;36(4):879-884. doi: 10.1007/s10067-017-3566-0. Epub 2017 Feb 6. Erratum in: Clin Rheumatol. 2019 Jan;38(1):269.

PMID:
28168661
44.

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies.

Tselios K, Gladman DD, Urowitz MB.

Open Access Rheumatol. 2016 Dec 20;9:1-9. doi: 10.2147/OARRR.S123549. eCollection 2017. Review.

45.

The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort.

Yap KS, Urowitz MB, Mahood Q, Medina-Rosas J, Sabapathy A, Lawson D, Su J, Gladman DD, Touma Z.

Semin Arthritis Rheum. 2017 Jun;46(6):791-797. doi: 10.1016/j.semarthrit.2016.09.008. Epub 2016 Sep 21.

PMID:
27769590
46.

Defining Low Disease Activity in Systemic Lupus Erythematosus.

Polachek A, Gladman DD, Su J, Urowitz MB.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):997-1003. doi: 10.1002/acr.23109. Erratum in: Arthritis Care Res (Hoboken). 2019 Apr;71(4):574.

47.

Breast cancer in systemic lupus.

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE.

Lupus. 2017 Mar;26(3):311-315. doi: 10.1177/0961203316664595. Epub 2016 Sep 30. Erratum in: Lupus. 2017 Nov;26(13):1459.

48.

Dr. Tselios, et al reply.

Tselios K, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2016 Sep;43(9):1767. doi: 10.3899/jrheum.160749. No abstract available.

PMID:
27587017
49.

Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus.

Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z.

Lupus. 2017 Apr;26(4):365-372. doi: 10.1177/0961203316664597. Epub 2016 Aug 20.

PMID:
27522094
50.

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.

Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, Heaney LG, Lightstone L, Lu N, Murrell DF, Petri M, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH.

Ann Rheum Dis. 2017 Mar;76(3):543-546. doi: 10.1136/annrheumdis-2016-210002. Epub 2016 Jul 29.

Supplemental Content

Loading ...
Support Center